Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Antonio Ledda

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
American Journal of Hematology|December 31, 2013
Genomic analysis of therapy-related acute promyelocytic leukemias arising after malignant and non-malignant disordersTiziana Ottone, Syed Khizer Hasan, Maria Teresa Voso, et al.
Blood|May 31, 2002
Unrelated donor bone marrow transplantation for thalassemia: the effect of extended haplotypesGiorgio La Nasa, Claudio Giardini, Francesca Argiolu, et al.
Annals of the New York Academy of Sciences|December 13, 2005
Unrelated bone marrow transplantation for beta-thalassemia patients: The experience of the Italian Bone Marrow Transplant GroupGiorgio La Nasa, Franca Argiolu, Claudio Giardini, et al.
Pathogens (Basel, Switzerland)|November 27, 2024
First Detection of West Nile Virus by Nasopharyngeal Swab, Followed by Phylogenetic AnalysisCarlo Zuddas, Sergio Piras, Stefano Cappai, et al.
Haematologica|April 10, 2002
Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myelomaPatrizia Tosi, Elena Zamagni, Claudia Cellini, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2009
Short-term thalidomide incorporated into double autologous stem-cell transplantation improves outcomes in comparison with double autotransplantation for multiple myelomaMichele Cavo, Francesco Di Raimondo, Elena Zamagni, et al.
Lancet (London, England)|December 15, 2010
Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 studyMichele Cavo, Paola Tacchetti, Francesca Patriarca, et al.
Annals of Hematology|May 11, 2013
Correlation between eight-gene expression profiling and response to therapy of newly diagnosed multiple myeloma patients treated with thalidomide-dexamethasone incorporated into double autologous transplantationCarolina Terragna, Matteo Renzulli, Daniel Remondini, et al.
Blood|January 6, 2016
Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myelomaValeria Magarotto, Sara Bringhen, Massimo Offidani, et al.
The Lancet. Oncology|November 14, 2021
Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trialFrancesca Gay, Pellegrino Musto, Delia Rota-Scalabrini, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
American Journal of Hematology|December 31, 2013
Genomic analysis of therapy-related acute promyelocytic leukemias arising after malignant and non-malignant disordersTiziana Ottone, Syed Khizer Hasan, Maria Teresa Voso, et al.
Blood|May 31, 2002
Unrelated donor bone marrow transplantation for thalassemia: the effect of extended haplotypesGiorgio La Nasa, Claudio Giardini, Francesca Argiolu, et al.
Annals of the New York Academy of Sciences|December 13, 2005
Unrelated bone marrow transplantation for beta-thalassemia patients: The experience of the Italian Bone Marrow Transplant GroupGiorgio La Nasa, Franca Argiolu, Claudio Giardini, et al.
Pathogens (Basel, Switzerland)|November 27, 2024
First Detection of West Nile Virus by Nasopharyngeal Swab, Followed by Phylogenetic AnalysisCarlo Zuddas, Sergio Piras, Stefano Cappai, et al.
Haematologica|April 10, 2002
Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myelomaPatrizia Tosi, Elena Zamagni, Claudia Cellini, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2009
Short-term thalidomide incorporated into double autologous stem-cell transplantation improves outcomes in comparison with double autotransplantation for multiple myelomaMichele Cavo, Francesco Di Raimondo, Elena Zamagni, et al.
Lancet (London, England)|December 15, 2010
Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 studyMichele Cavo, Paola Tacchetti, Francesca Patriarca, et al.
Annals of Hematology|May 11, 2013
Correlation between eight-gene expression profiling and response to therapy of newly diagnosed multiple myeloma patients treated with thalidomide-dexamethasone incorporated into double autologous transplantationCarolina Terragna, Matteo Renzulli, Daniel Remondini, et al.
Blood|January 6, 2016
Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myelomaValeria Magarotto, Sara Bringhen, Massimo Offidani, et al.
The Lancet. Oncology|November 14, 2021
Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trialFrancesca Gay, Pellegrino Musto, Delia Rota-Scalabrini, et al.
Pageof 3